Chromicent GmbH is a Pharmaceutical Service Provider and was founded on December 30th, 2013.
Since March 2015 Chromicent hold a GMP certificate.
At the location in Berlin-Adlershof, in the Centre for Photovoltaics and Renewable Energies (ZPV), there are offices, training and seminar rooms on an area of 550 square metres, as well as a spacious laboratory wing of approx. 350 square metres.
Philosophy
Healthcare is one of the central issues of the future. The development of medicines and pharmaceutical products plays a significant role in this.
Access to affordable, safe medicines for a growing world population is one of the challenges of our time.
The importance of quality control of medicines may only be apparent at second glance in this context.
Technological progress, shorter product life cycles, growing demands on quality and price (health insurance companies) and the ever-increasing demand for low-cost medicines are increasingly forcing the pharmaceutical industry to act cost-effectively, e.g. by outsourcing development and production to international countries or making drastic savings in the laboratory sector.
This is not without risks. Patent infringements and drug counterfeiting (melamine-in-milk powder scandal in China, heparin scandal, clopidogrel scandal in India) are just a few examples.
The quality control of the future requires robust, fast, simple and cost-effective methods that do not disregard environmental protection and occupational health and safety in order to guarantee affordable and, above all, safe medicines for each and every one of us.
Efficiency and productivity are key to the success of any company. In order to be able to develop and manufacture the medicines of the future competitively both nationally and internationally, innovation is needed. This is especially true in the area of method development.
Chromicent is an innovator in this field. Chromicent is the first and only company to use method development by means of Quality-by-Design within Method Lifecycle Management.
Innovative analytical methods are the decisive tool for all development and manufacturing steps of a drug in order to be able to evaluate the quality of a product. The consistent quality-by-design approach in method development, the expertise and experience of our scientists and our vision of a just health policy make us your partner. Let us combine economic thinking, scientific innovation and humanitarian action.
Founders
Chromicent GmbH’s founders Dr. Alexander H. Schmidt (CEO) and Mijo Stanic (CEO) have gained decades of leadership in pharmaceutical research. Their expertise lies within development of analytical methods using a quality-by-design approach as well as method validation, analytical instrument qualification (AIQ), increasing efficiency in the lab and GMP compliance.
